Nuvectis Pharma (NVCT) Competitors

Vir Biotechnology (NASDAQ:VIR) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation.

Which has more risk & volatility, VIR or NVCT?

Vir Biotechnology has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500.

Do analysts prefer VIR or NVCT?

Vir Biotechnology currently has a consensus price target of $33.57, suggesting a potential upside of 452.16%. Nuvectis Pharma has a consensus price target of $17.00, suggesting a potential upside of 76.72%. Given Vir Biotechnology's higher possible upside, research analysts clearly believe Vir Biotechnology is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Nuvectis Pharma	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to VIR or NVCT?

In the previous week, Nuvectis Pharma had 1 more articles in the media than Vir Biotechnology. MarketBeat recorded 6 mentions for Nuvectis Pharma and 5 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.68 beat Nuvectis Pharma's score of 0.21 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvectis Pharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher earnings & valuation, VIR or NVCT?

Nuvectis Pharma has lower revenue, but higher earnings than Vir Biotechnology. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$63.71M	13.18	-$615.06M	-$3.82	-1.59
Nuvectis Pharma	N/A	N/A	-$22.26M	-$1.11	-8.67

Do institutionals and insiders believe in VIR or NVCT?

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 15.6% of Vir Biotechnology shares are held by company insiders. Comparatively, 35.8% of Nuvectis Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Is VIR or NVCT more profitable?

Nuvectis Pharma has a net margin of 0.00% compared to Vir Biotechnology's net margin of -678.40%. Vir Biotechnology's return on equity of -36.71% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-678.40%	-36.71%	-31.00%
Nuvectis Pharma	N/A	-155.80%	-104.02%

Does the MarketBeat Community prefer VIR or NVCT?

Vir Biotechnology received 44 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 92.86% of users gave Nuvectis Pharma an outperform vote while only 56.44% of users gave Vir Biotechnology an outperform vote.

Company	Underperform	Outperform
Vir Biotechnology	Outperform Votes 57 56.44%	Underperform Votes 44 43.56%
Nuvectis Pharma	Outperform Votes 13 92.86%	Underperform Votes 1 7.14%

Summary

Vir Biotechnology beats Nuvectis Pharma on 9 of the 17 factors compared between the two stocks.